With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...

GlaxoSmithKline PLC GSK 0.79% has reported positive results from a study of a cancer drug in a clinical trial that a senior figure in the company said justified the decision to acquire cancer ...

Sanofi and GlaxoSmithKline are trailing other drugmakers in the race to distribute COVID-19 inoculations despite being two of the world’s biggest vaccine businesses.

GlaxoSmithKline is cutting employees in China, as the U.K. drug company grapples with accusations from Beijing that it bribed doctors and officials to boost sales.

GlaxoSmithKline (GSK-0.81%) has confirmed plans to separate its consumer and pharmaceutical business units. However, an activist investor appears to want the big drugmaker to take more drastic ...

GlaxoSmithKline's chief executive officer said in an email to the company’s employees that Slaoui’s name would be removed from its research and development facility in Rockville, Md.

July 14, 2010 -- In the face of mounting evidence that GlaxoSmithKline withheld important safety data on their controversial drug Avandia, some doctors are abandoning use of this diabetes treatment.

GlaxoSmithKline is accused in a lawsuit of using threats to block generic competition to its $2-billion-a-year antibiotic Augmentin after a U.S. judge eliminated the drug's patent protection.